OS Benefit to Adding Fulvestrant to First-Line Anastrozole in HR-Positive Metastatic Breast Cancer - Cancer Therapy Advisor

OS Benefit to Adding Fulvestrant to First-Line Anastrozole in HR-Positive Metastatic Breast Cancer  Cancer Therapy Advisor

The survival benefit of anastrozole/fulvestrant combination therapy was more pronounced in the subgroup of patients who did not have prior exposure to ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more